

<https://helda.helsinki.fi>

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia : Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age

Rank, Cecilie U.

2020-01-10

Rank , C U , Wolthers , B O , Grell , K , Albertsen , B K , Frandsen , T L , Overgaard , U M , Toft , N , Nielsen , O J , Wehner , P S , Harila-Saari , A , Heyman , M M , Malmros , J , Abrahamsson , J , Noren-Nystrom , U , Tomaszewska-Toporska , B , Lund , B , Jarvis , K B , Quist-Paulsen , P , Vaitkeviciene , G E , Griskevicius , L , Taskinen , M , Wartiovaara-Kautto , U , Lepik , K , Punab , M , Jonsson , O G & Schmiegelow , K 2020 , '

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia : Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age ' , Journal of Clinical Oncology , vol. 38 , no. 2 , pp. 145-+ . <https://doi.org/10.1200/JCO.19.02208>

<http://hdl.handle.net/10138/311328>

<https://doi.org/10.1200/JCO.19.02208>

unspecified

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age

Cecilie U. Rank, MD^{1,2}; Benjamin O. Wolthers, MD, PhD¹; Kathrine Grell, PhD^{1,2}; Birgitte K. Albertsen, MD, PhD³; Thomas L. Frandsen, MD, PhD¹; Ulrik M. Overgaard, MD¹; Nina Toft, MD, PhD⁴; Ove J. Nielsen, MD, DrMedSci¹; Peder S. Wehner, MD, PhD⁵; Arja Harila-Saari, PhD, MD⁶; Mats M. Heyman, MD, PhD⁷; Johan Malmros, MD, PhD⁷; Jonas Abrahamsson, PhD, MD⁸; Ulrika Norén-Nyström, MD, PhD⁹; Beata Tomaszewska-Toporska, MD¹⁰; Bendik Lund, MD, PhD¹¹; Kirsten B. Jarvis, MD^{12,13}; Petter Quist-Paulsen, MD, PhD¹¹; Goda E. Vaitkeviciene, MD, PhD^{14,15}; Laimonas Griškevičius, MD, PhD^{14,15}; Mervi Taskinen, MD, PhD¹⁶; Ulla Wartiovaara-Kautto, MD, PhD¹⁶; Kristi Lepik, MD¹⁷; Mari Punab, MD¹⁸; Ólafur G. Jónsson, MD¹⁹; and Kjeld Schmiegelow, MD, DrMedSci^{1,2}

abstract

PURPOSE Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored.

PATIENTS AND METHODS We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.

RESULTS Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; *P* = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; *P* = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; *P* = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; *P* = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; *P* = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse.

CONCLUSION Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse.

ASSOCIATED CONTENT

Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on October 10, 2019 and published at ascopubs.org/journal/jco on November 26, 2019; DOI <https://doi.org/10.1200/JCO.19.02208>

J Clin Oncol 38:145-154. © 2019 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License 

INTRODUCTION

Because adult patients now more frequently receive pediatric-inspired acute lymphoblastic leukemia (ALL) treatment, their tolerance to such therapy has become an important issue.^{1,2} Depending on the extent of asparaginase (ASP) exposure, larger trials report asparaginase-associated pancreatitis (AAP) in up to 11% of children with ALL.³⁻¹⁶ Furthermore, premature withdrawal of ASP reduces cure rates,^{3,4,17} and one of the commonest causes of ASP truncation in children is AAP

because many experience a second AAP after ASP rechallenge.^{3,5,18}

ASP depletes the body of asparagine,¹⁹ interfering with the highly active pancreatic protein synthesis. Acute pancreatitis arises from premature activation of trypsin within pancreatic acinar cells, acinar cell destruction, concomitant local inflammation, and ultimately pancreatic autodigestion.²⁰ However, the direct mechanism behind AAP is unknown, and treatment is mainly supportive.²¹ Although mortality is reported in only a small percentage of patients,^{3,6,7,13,18,22} both

acute and long-term morbidities after childhood AAP are common.^{13,18,22-24}

Some clinical^{3-9,15,18,25} and genetic^{5,9,26} risk factors for acute pancreatitis have been proposed, including adolescent age. However, comparative studies of pediatric and adult patients with ALL, as well as studies exploring the AAP-related morbidity and impact on leukemic relapse risk, are missing. We investigated the cumulative incidence, clinical characteristics, and relapse risk in patients with ALL with AAP aged 1.0-45.9 years uniformly treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.

PATIENTS AND METHODS

Study Population

A total of 2,448 patients (including 168 patients with AAP) aged 1.0-45.9 years with a diagnosis of either B-cell precursor or T-cell Philadelphia chromosome-negative

ALL between July 2008 and October 2018 were included. All patients were treated according to the NOPHO ALL2008 protocol in Denmark, Estonia, Finland, Iceland, Lithuania, Norway, and Sweden. An inclusion flowchart is presented in the Data Supplement.

All centers complied with mandatory registration of AAP 4 times a year throughout the study period.^{27,28} We identified patients with AAP in the NOPHO ALL registry on April 2, 2019, which provided data on patient, disease, and antileukemic treatment. Detailed questionnaires in relation to the diagnosis, complications, and outcome of AAP were subsequently completed by local clinicians. The data were merged with previously published data from 60% (80/134) of the pediatric cohort.⁵

AAP-Related Definitions

The diagnosis of acute pancreatitis required fulfillment of at least 2 of 3 diagnostic criteria: (1) abdominal pain; (2) serum amylase (total or pancreas specific) or lipase

TABLE 1. AAP Characteristics

Characteristic	All	Age (years)		
		1.0-9.9	10.0-17.9	18.0-45.0
No. of patients (%)	168	96 (57)	38 (23)	34 (20)
Treatment phase				
SR/IR consolidation 1	63 (38)	44 (46)	13 (34)	6 (18)
SR/IR delayed intensification 1/consolidation 2	46 (27)	19 (20)	11 (29)	16 (46)
SR/IR maintenance 1	30 (18)	18 (19)	6 (16)	6 (18)
HR block treatment	27 (16)	15 (15)	6 (16)	6 (18)
HR delayed intensification	1 (0.5)	0	1 (2.5)	0
HR maintenance 1	1 (0.5)	0	1 (2.5)	0
Symptoms at AAP diagnosis				
Abdominal pain*	166 (99)	94 (98)	38 (100)	34 (100)
Vomiting/missing	106 (66)/7	60 (64)/2	28 (80)/3	18 (56)/2
Nausea/missing	113 (74)/16	59 (68)/9	30 (91)/5	24 (75)/2
Back pain/missing	36 (26)/27	17 (22)/18	11 (34)/6	8 (26)/3
AAP grade†				
1	21 (13)	19 (20)	0	2 (6)
2	140 (83)	72 (75)	37 (97)	31 (91)
3	3 (2)	1 (1)	1 (3)	1 (3)
Missing	4	4	0	0
ASP re-exposure‡	34 (20)	28 (29)	3 (8)	3 (9)
Second AAP	15 (44)	11 (39)	2 (67)	2 (67)

NOTE. All data are No. (%).

Abbreviations: AAP, asparaginase-associated pancreatitis; ASP, asparaginase; HR, high risk; IR, intermediate risk; SR, standard risk.

*Abdominal pain persisted > 72 hours in 80% of the patients with AAP with this information available (124/155, unknown in 13 patients).

†Grading included: (1) mild AAP with symptoms and enzyme elevations lasting < 72 hours; (2) severe AAP with symptoms and/or enzyme elevations lasting > 72 hours or hemorrhagic pancreatitis, pancreatic abscess, or pseudocyst; and (3) death from AAP.

‡Two patients with planned polyethylene glycol conjugated *Escherichia coli*-derived ASP (PegASP) re-exposure developed a second episode of acute pancreatitis before restart of PegASP (not included). PegASP was replaced with *Erwinia chrysanthemi*-derived ASP due to allergy in 3 patients after the first AAP event, of whom none developed a second AAP. Five patients developed first-time AAP after the last ASP dose in the protocol treatment and, thus, could not be rechallenged with PegASP.

≥ 3 times the upper normal limit; and (3) ultrasound, computed tomography, or magnetic resonance imaging compatible with pancreatitis according to the international Ponte di Legno consensus criteria.²⁹ The definition of AAP in this study required a diagnosis within 4 weeks after the last ASP injection—the cutoff time point of measurable polyethylene glycol conjugated *Escherichia coli*-derived ASP (PegASP) activity.³⁰ Definitions of grading and complications are presented in the Data Supplement and Tables 1 and 2.

ALL2008 Protocol Treatment

Therapy details on the NOPHO ALL2008 protocol have been reported previously.^{2,27,28,31} Treatment was based on stratification into 4 risk groups: standard risk (SR);

intermediate risk (IR); high risk (HR); and high risk with hematopoietic stem cell transplantation (HR-SCT) in first complete remission (CR1), guided by tumor burden at diagnosis, immunophenotype, cytogenetics, CNS involvement, and minimal residual disease levels on treatment days 15, 29, and 79 (or after the second HR block). SR and IR patients received identical PegASP treatment. Of note, children (SR and IR) were randomly assigned to receive PegASP, 1,000 IU/m²/dose intramuscularly, either at 2-week (control arm) or 6-week (experimental arm) intervals from weeks 14 to 33 (ClinicalTrials.gov identifier: NCT00819351). All children received PegASP at 6-week intervals from week 14 after the randomization closed on March 1, 2016.³² The randomization did not influence

TABLE 2. AAP-Related Complications

Complication	All	1.0-9.9 years	10.0-17.9 years	18.0-45.0 years
SIRS*	103 (72)/24	66 (75)/8	22 (88)/6	15 (63)/10
Body temperature > 38°C or < 36°C/missing	57 (35)/6	35 (37)/2	14 (40)/3	8 (24)/1
Heart rate > 90 beats/min/missing	107 (69)/14	64 (69)/3	24 (71)/4	19 (70)/7
Respiratory rate > 20 breaths/min/missing	43 (37)/53	31 (42)/23	9 (38)/14	3 (17)/16
WBC > 12 × 10 ⁹ /L or < 4 × 10 ⁹ /L/missing	98 (61)/7	62 (68)/5	19 (51)/1	17 (52)/1
Systolic blood pressure ≤ 100 mmHg	52 (33)/11	28 (30)/3	17 (49)/3	7 (24)/5
ICU admission	65 (39)	30 (31)	21 (55)	14 (41)
Assisted mechanical ventilation	14 (22)	7 (23)	4 (19)	3 (21)
Vasopressor support/missing	18 (29)/2	6 (20)	7 (37)/2	5 (36)
Need of acute insulin therapy†	32 (19)	11 (11)	14 (37)	7 (21)
Need of permanent insulin therapy	18 (11)	3 (3)	8 (21)	7 (21)
Pancreatic pseudocysts	45 (27)/1	15 (16)/1	17 (45)	13 (38)
Drainage	19 (42)	4 (27)	11 (65)	4 (31)
Recurrent abdominal pain at last follow-up	15 (10)/11	6 (7)/6	7 (23)/4	2 (6)/1
Elevated pancreatic enzymes at last follow-up	9 (6)/19	3 (3)/10	5 (17)/8	1 (3)/1
Imaging compatible with pancreatitis at last follow-up	11 (7)/15	3 (3)/10	6 (18)/4	2 (6)/1
Inflammation/edema‡	3 (27)	2 (67)	0	1 (50)
Pancreatic pseudocysts§	6 (55)	1 (33)	3 (50)	2 (100)
Hemorrhage	2 (18)	0	2 (33)	0
AAP-related death¶	3 (2)	1 (1)	1 (3)	1 (3)
Any complication#	95 (57)	44 (46)	31 (82)	20 (59)
Any acute complication	90 (54)	40 (42)	30 (79)	20 (59)
Any persisting complication	33 (20)	8 (8)	16 (42)	9 (26)

NOTE. All data are No. (%) or No. (%) /missing.

Abbreviations: AAP, asparaginase-associated pancreatitis; ICU, intensive care unit; SIRS, systemic inflammatory response syndrome.

*SIRS definition: ≥ 2 of 4 criteria, including body temperature > 38 or < 36°C, heart rate > 90 beats/min, respiratory rate > 20 breaths/min, and WBC > 12 × 10⁹/L or < 4 × 10⁹/L.

†One patient presented with diabetic ketoacidosis at AAP diagnosis.

‡Persisting inflammation/edema in 1 patient and development of inflammation/edema after AAP diagnosis in 1 patient.

§Persisting pseudocysts in 3 patients and development of pseudocysts after AAP diagnosis in 3 patients.

||Development of hemorrhage after AAP diagnosis in 2 patients.

¶AAP diagnosis postmortem in 1 patient.

#Any known complication included acute complications (ICU admission, acute insulin need, development of pancreatic pseudocysts, and AAP-related death) and persisting complications (permanent insulin need, recurrent abdominal pain, elevated pancreatic enzymes at last follow-up, and imaging compatible with pancreatitis at last follow-up).

cure rates.³² Patients aged ≥ 18 years and treated at an adult clinic were not included in the PegASP randomization; however, adults from Estonia, Lithuania, and Sweden received PegASP at 6-week intervals from March, September, and April 2016, respectively. The adult centers from the remaining countries continued PegASP treatment according to the control arm. The NOPHO ALL2008 protocol is presented in the Data Supplement.

The study was approved by the regional research ethics committee of the Capital Region of Denmark (Protocol No. H-2-2010-002) and the Danish Data Protection Agency (Journal No. 2012-58-0004). All patients gave written informed consent, and the study was conducted in accordance with the Declaration of Helsinki (version 2008; www.wma.net).

Statistical Analyses

Patients were followed from the time of ALL diagnosis until the date of the first event (relapse, death during induction or in CR1, or second malignant neoplasm [SMN]); SCT in CR1; loss to follow-up/abandonment of therapy; or last follow-up in the registry or April 2, 2019, whichever came first. When exploring AAP, patients were followed from day 30 (the time of the first ASP dose) until the date of the first event including censoring 4 weeks after the last planned ASP injection or 4 weeks after the ASP truncation date, if available, respectively. The reversed Kaplan-Meier method was used to estimate the follow-up time. Cumulative incidences were estimated using the Aalen-Johansen estimator considering relapse, death, and SMN as competing events; the estimates were compared using Gray's test. The body mass index z-scores were calculated accounting for age and sex according to Danish references.³³ Time to first AAP was analyzed in a Cox proportional hazards regression model including relevant preselected clinical characteristics. As a sensitivity analysis of the predefined age groups (1.0-9.9 years, 10.0-17.9 years, and 18.0-45.9 years), new age groups were explored, each containing approximately 25% of the AAP events (1.0-4.9 years, 5.0-8.9 years, 9.0-16.9 years, and 17.0-45.9 years). Investigating potential risk factors of AAP-related complications, preselected clinical variables were included in a multiple logistic regression model of development of any AAP-related complication within ≥ 100 days after the AAP diagnosis. To investigate the association between AAP and time to death in CR1 and relapse, we used Cox models with AAP as a time-dependent variable and delayed entry on the CR1 date, respectively. As sensitivity analyses, the models were stratified by risk group on day 29 with delayed entry on day 29 or the CR1 date, if later than day 29. In all Cox models, relevant interactions and the proportional hazards assumption were explored. Two-sided P values $< .05$ were regarded as statistically significant.

RESULTS

Patient and Treatment Characteristics

Following all patients for a median of 245 days (interquartile range [IQR], 186-259), the day 280 cumulative incidence of first-time AAP (168/2,448) was 8.3% (95% CI, 7.0 to 9.9) with all but 1 late AAP included at this time point. The day 280 cumulative incidences were 7.0% (95% CI, 5.4 to 8.6), 10.1% (95% CI, 7.0 to 13.3), and 11.0% (95% CI, 7.1 to 14.9) in patients aged 1.0-9.9 years, 10.0-17.9 years, and 18.0-45.9 years, respectively ($P = .03$; Data Supplement). However, when analyzing the 4 new age groups, the risk of AAP already rose at 5 years of age, being 5.4% (95% CI, 3.2 to 7.5) in patients aged 1.0-4.9 years, 10.2% (95% CI, 7.2 to 13.1) in patients aged 5.0-8.9 years, 10.4% (95% CI, 7.3 to 13.4) in patients aged 9.0-16.9 years, and 11.3% (95% CI, 7.6 to 14.9) in patients aged 17.0-45.9 years ($P < .001$; Fig 1). The clinical characteristics of the patients appear in Tables 1 and 3. None of the patients had a prior history of pancreatitis or any known comorbidity, particularly of the liver and pancreas.

AAP occurred within a median of 10 days (IQR, 6-13; range, 0-28) from last PegASP exposure after a median number of 5 PegASP doses in total (IQR, 3-7; range, 1-14). PegASP was replaced with *Erwinia chrysanthemi*-derived ASP because of allergy in 1 patient before the AAP event. The PegASP activity was measurable in 98% of the AAP patients during treatment with this information available (86/88, unknown in 80 patients). Of note, in 6 of the excluded 8 patients with acute pancreatitis occurring more than 4 weeks after the last PegASP dose, acute pancreatitis occurred within 32-90 days (median, 38 days) after the last PegASP dose. The remaining 2 patients developed acute pancreatitis 210 and 589 days, respectively, after the last PegASP dose (Data Supplement).

In a multiple Cox regression analysis (including sex, immunophenotype, and WBC), the hazard of AAP was doubled already since the age of 5 years (Table 4). Hence, patients aged 5.0-8.9 years demonstrated an HRa of 2.3 (95% CI, 1.5-3.6; $P < .0001$), patients aged 9.0-16.9 years demonstrated an HRa of 2.5 (95% CI, 1.6-3.8, $P < .0001$), and patients aged 17.0-45.9 years demonstrated an HRa of 2.5 (95% CI, 1.6 to 3.8; $P < .0001$; Table 4). No difference in the estimates was observed when including the initially excluded 8 patients diagnosed with acute pancreatitis more than 4 weeks after the last PegASP dose as a sensitivity analysis (results not shown). Additionally, the above-mentioned associations remained unchanged when stratifying by induction glucocorticoids (prednisolone v dexamethasone) or by day 29 minimal residual disease-guided risk group (SR v IR v HR/HR-SCT), respectively (results not shown).




FIG 1. The cumulative incidence of first-time asparaginase-associated pancreatitis (AAP) by age groups with 95% CIs and patients at risk. The day 280 cumulative incidences were 5.4% (95% CI, 3.2 to 7.5) for patients aged 1.0-4.9 years; 10.2% (95% CI, 7.2 to 13.1) for patients aged 5.0-8.9 years; 10.4% (95% CI, 7.3 to 13.4) for patients aged 9.0-16.9 years; and 11.3% (95% CI, 7.6 to 14.9) for patients aged 17.0-45.9 years. Of note, day 280 from acute lymphoblastic leukemia diagnosis to event corresponds to day 250 on the x-axis because of entry for all patients on day 30 (the time of the first polyethylene glycol conjugated *Escherichia coli*-derived ASP [PegASP] dose).

AAP-Related Complications and Mortality

Of the 9 patients who presented with hemorrhagic and/or necrotizing pancreatitis at AAP diagnosis, 33% (3/9) had persisting symptoms and signs of chronic pancreatitis at last follow-up, and 1 of these died as a result of AAP (Table 2). Forty-five patients developed pseudocysts (27%; 45/167 with this information available), of whom 21% (9/43; unknown in 2 patients) had recurrent abdominal pain at last follow-up (Table 2).

In a sex-adjusted multiple logistic regression of any AAP-related complication (ie, AAP-related death; intensive care unit admission; acute and permanent need for insulin therapy; development of pancreatic pseudocysts; recurrent abdominal pain; elevated pancreatic enzymes at last follow-up; and imaging at last follow-up showing pancreatic inflammation/edema, pseudocysts, or hemorrhage), only patients with ≥ 100 days of follow-up after the AAP diagnosis (160/168) were included (median follow-up, 2.3 years; IQR, 1.3-4.2). Patients aged 10.0-17.9 years demonstrated more than 4-fold increased odds of developing any of these AAP-related complications (OR, 4.4; 95% CI, 1.7 to 11.2; $P = .002$), compared with patients aged 1.0-9.9 years (Table 5). Neither age ≥ 18.0 years (OR, 1.5; 95% CI, 0.7 to 3.5; $P = .3$) compared with children aged 1.0-9.9 years nor sex was associated with development of any AAP-related complication (Table 5). When including the 4 new age groups as a sensitivity analysis, both adolescents aged 9.0-16.9 years and adults aged 17.0-45.9 years had

increased odds of developing any AAP-related complication (9.0-16.9 years: OR, 7.3, 95% CI, 2.7 to 19.7; $P = .0001$; and 17.0-45.9 years: OR, 2.6; 95% CI, 1.1 to 6.4; $P = .04$; Data Supplement), compared with children aged 1.0-4.9 years.

When analyzing development of any acute AAP-related complication (ie, AAP-related death, acute insulin need, intensive care unit admission, and pancreatic pseudocyst development), only patients aged 10.0-17.9 years had increased odds of developing any acute complication (OR, 5.2; 95% CI, 2.1 to 13.2; $P = .0005$), compared with patients aged 1.0-9.9 years (Table 5; Data Supplement). Odds of developing any persisting AAP-related complication (ie, elevated pancreatic enzymes at last follow-up; imaging at last follow-up showing pancreatic inflammation/edema, pseudocysts, or hemorrhage; permanent insulin need; and recurrent abdominal pain) were increased for patients aged 10.0-17.9 years (OR, 6.7; 95% CI, 2.4 to 18.4; $P = .0002$) and patients aged 18.0-45.9 years (OR, 4.1; 95% CI, 1.4 to 11.8; $P = .01$), compared with patients aged 1.0-9.9 years (Table 5; Data Supplement). Notably, in the sensitivity analysis, patients aged 5.0-8.9 years did not have increased odds of developing any persisting AAP-related complication (OR, 1.7; 95% CI, 0.3 to 10.8; $P = .6$), compared with patients aged 1.0-4.9 years (Data Supplement).

Death from any cause occurred as the first event in 81 of 2,448 patients, including 5 AAP patients, of whom 3 aged 8.6, 17.3, and 18.6 years died as a result of first-time AAP within 0-29 days from AAP diagnosis (AAP was an unexpected autopsy finding in 1 patient). In an age- and sex-adjusted Cox analysis of time to death in CR1, no difference was found when comparing AAP patients with non-AAP patients (HRa, 0.4; 95% CI, 0.05 to 2.6; $P = .3$; remaining results not shown). Stratifying the above-mentioned models by risk group on day 29 did not change the results.

Asparaginase Re-Exposure and Relapse

Approximately one fifth (34/168) of the patients with AAP were rechallenged with ASP, of whom 44% (15/34) developed a second episode of AAP after a median of 2 ASP doses (IQR, 1-3; range, 1-7); 40% (6/15) were severe (Table 1). Development of a second AAP episode after ASP re-exposure was not significantly associated with age (Data Supplement). No patient with a second AAP episode was further re-exposed to ASP.

Leukemic relapse in CR1 occurred in 196 of 2,448 patients during the study period, including 21 AAP patients, among whom PegASP was truncated in 81% (17/21) because of AAP. The age- and sex-adjusted hazard of relapse among patients with AAP who were truncated in ASP was not significantly increased when comparing with patients with AAP who were re-exposed

TABLE 3. Baseline Characteristics

Characteristic	No. (%)	Day 280 Cumulative Incidence of First-Time AAP (%)	95% CI	P
All patients (delayed entry on day 30)	2,380	8.3	7.0 to 9.9	—
Age groups (years; predefined)				.03
1.0-9.9	1,587 (67)	7.0	5.4 to 8.6	
10.0-17.9	415 (17)	10.1	7.0 to 13.3	
18.0-45.9	378 (16)	11.0	7.1 to 14.9	
Age groups (years; sensitivity analysis)				< .001
1.0-4.9	1,065 (45)	5.4	3.2 to 7.5	
5.0-8.9	453 (19)	10.2	7.2 to 13.1	
9.0-16.9	435 (18)	10.4	7.3 to 13.4	
17.0-45.9	427 (18)	11.3	7.6 to 14.9	
Sex				.8
Female	1,019 (43)	7.7	5.9 to 9.4	
Male	1,361 (57)	8.7	6.6 to 10.8	
Immunophenotype				.4
BCP	1,992 (84)	8.8	6.9 to 10.8	
T -cell	388 (16)	6.9	4.2 to 9.6	
WBC				.2
< 100 × 10 ⁹ /L	2,056 (86)	8.8	7.0 to 10.7	
≥ 100 × 10 ⁹ /L	323 (14)	6.3	3.5 to 9.2	
Missing	1	—	—	
BMI				.5
≤ −2 SD	117 (5)	7.1	2.4 to 11.8	
> −2 SD to < +2 SD	2,066 (87)	8.2	6.6 to 9.8	
≥ +2 SD	164 (7)	9.8	5.1 to 14.6	
Missing	33 (1)	—	—	
Induction treatment				.1
Dexamethasone	539 (23)	6.2	4.1 to 8.4	
Prednisolone	1,841 (77)	9.5	7.0 to 12.1	
Treatment group day 29*				.6
SR	1,057 (44)	8.8	5.8 to 11.9	
IR	875 (37)	10.8	5.3 to 16.4	
HR/HR-SCT	429 (18)	7.1	4.5 to 9.8	
Missing	19 (1)	—	—	

Abbreviations: AAP, asparaginase-associated pancreatitis; BCP, B-cell precursor; BMI, body mass index; HR/HR-SCT, high risk/high risk with hematopoietic stem cell transplantation; IR, intermediate risk; SD, standard deviations; SR, standard risk.

*Protocol treatment was modified with the addition of 1 cycle of blinatumomab because of poor treatment response in 1 patient, nelarabine because of poor treatment response in 2 patients, and imatinib because of BCR-ABL translocation in 1 patient.

to ASP (5.0-year cumulative incidence of relapse: 13.2% v 14.2%; HRa, 1.0; 95% CI, 0.3 to 3.1; $P = .97$). Moreover, no difference between patients with AAP versus patients without AAP was found in an age- and sex-adjusted Cox analysis (HRa, 1.7; 95% CI, 0.8 to 3.3; $P = .1$; remaining results not shown). Stratifying the abovementioned models by risk group on day 29 did not change the results.

DISCUSSION

Despite superior cure rates for children versus adults with ALL, many centers do not use pediatric ALL protocols, partly because of worries about risk of toxicities. Because ASP plays a crucial role in pediatric ALL protocols, the present findings of no increased AAP risk in adults compared with children down to the age of 5 years—in spite of an ASP-heavy protocol—are comforting and in accordance with

TABLE 4. Multiple Cox Regression Analysis of Time to First AAP (n = 2,379)

Variable	No.	AAP-Specific HRa	95% CI	P
Cox model 1				
Age groups (years; predefined)				
1.0-9.9	1,587	ref		
10.0-17.9	415	1.6	1.1 to 2.3	.02
18.0-45.9	377	1.6	1.1 to 2.4	.02
Sex				
Female	1,018	ref		
Male	1,361	1.0	0.8 to 1.4	.9
Immunophenotype				
BCP	1,992	ref		
T cell	387	0.8	0.5 to 1.3	.3
WBC				
< 100 × 10 ⁹ /L	2,056	ref		
≥ 100 × 10 ⁹ /L	323	0.8	0.5 to 1.3	.4
Cox model 2				
Age groups (years; sensitivity analysis)				
1.0-4.9	1,065	ref		
5.0-8.9	453	2.3	1.5 to 3.6	< .001
9.0-16.9	435	2.5	1.6 to 3.8	< .001
17.0-45.9	426	2.5	1.6 to 3.8	< .001
Sex				
Female	1,018			
Male	1,361	1.0	0.8 to 1.4	.8
Immunophenotype				
BCP	1,992	ref		
T cell	387	0.7	0.4 to 1.1	.1
WBC				
< 100 × 10 ⁹ /L	2,056	ref		
≥ 100 × 10 ⁹ /L	323	0.8	0.5 to 1.3	.4

NOTE. The table includes 2 Cox models including the predefined age groups and the new age groups as sensitivity analysis, respectively. Abbreviations: AAP, asparaginase-associated pancreatitis; BCP, B-cell precursor; HRa, AAP hazard ratios; ref, reference.

previous studies.^{34,35} Moreover, our findings are compatible with previous pediatric studies reporting more than a 2-fold increased AAP risk in patients older than 9 years of age.^{3,4,8,15,25} This similarity between older children and young adults with ALL has also recently been demonstrated for thromboembolic complications.²

Additionally, the odds of any AAP-related complication were increased by more than 7-fold in adolescents aged 9.0-16.9 years and more than 2-fold in adults aged 17.0-45.9 years, compared with younger children aged 1.0-4.9 years. In fact, adolescents had the most pronounced increase in odds, demonstrating more than 7-fold increased odds of any acute complication and more than 12-fold increased odds of any persisting complication, compared with the youngest children. This emphasizes

the striking vulnerability of this age group, although the reasons hereof are unknown. Changes in endogenous sex hormones may give rise to the increased frequency of insulin resistance and (pre)metabolic syndrome during puberty,³⁶ which has been associated with dyslipidemia and decreased antioxidant capacity.³⁷ Oxidative stress and inflammation play a pivotal role in the pathogenesis of pancreatitis—and probably also in the development of pancreatitis-related complications.^{38,39}

In contrast to age, the role of genetic predisposition is less clear. Recent genome-wide association studies have found different candidate single-nucleotide polymorphisms associated with pancreatitis in patients with ALL^{5,9,26}; however, only *rs13228878* and *rs10273639* associated with

TABLE 5. Multiple Logistic Regression of AAP-Related Complications (n = 160)

AAP-Related Complication	No.	OR*	95% CI	P
Any AAP-related complication*				
Age groups (years; predefined)				
1.0-9.9	93	ref		
10.0-17.9	34	4.4	1.7 to 11.2	.002
18.0-45.9	33	1.5	0.7 to 3.5	.3
Sex				
Female	71	ref		
Male	89	1.2	0.6 to 2.3	.6
Any acute AAP-related complication†				
Age groups (years; predefined)				
1.0-9.9	93	ref		
10.0-17.9	34	5.2	2.1 to 13.2	< .001
18.0-45.9	33	1.8	0.8 to 4.1	.1
Sex				
Female	71	ref		
Male	89	1.3	0.7 to 2.6	.4
Any persisting AAP-related complication‡				
Age groups (years; predefined)				
1.0-9.9	93	ref		
10.0-17.9	34	6.7	2.4 to 18.4	< .001
18.0-45.9	33	4.1	1.4 to 11.8	.01
Sex				
Female	71	ref		
Male	89	0.9	0.4 to 2.0	.7

Abbreviations: AAP, asparaginase-associated pancreatitis; OR, odds ratio; ref, reference; ref, reference.

*OR of any AAP-related complication (acute and persisting).

†OR of any AAP-related complication including intensive care unit admission, acute insulin therapy, development of pancreatic pseudocysts, and AAP-related death.

‡OR of any persisting AAP-related complication including permanent insulin therapy, recurrent abdominal pain at last follow-up, elevated pancreatic enzymes at last follow-up, and imaging compatible with pancreatitis at last follow-up.

elevated expression of the *PRSS1* gene encoding for trypsinogen have been validated.²⁶

The early onset of AAP coincided with the PegASP administration, yet the cumulative PegASP dose up to the time of AAP ranged from 1,000 to 14,000 IU/m². Substantial evidence supports that the AAP risk is proportional to the number of doses administered.^{9,32} Notably, this is in contrast to ASP hypersensitivity, which in general occurs after the first few doses.⁴⁰ Although premature withdrawal of ASP has been linked to inferior survival⁴ and PegASP was truncated in the majority of patients with AAP (80%) in our study, neither AAP nor truncation of ASP because of AAP was associated with increased risk of relapse, potentially reflecting low study power in this regard. When looking at ASP re-exposure,

44% of those who were rechallenged with PegASP in our study developed a second event of acute pancreatitis (40% being severe cases), which is in accordance with previous findings in pediatric studies.^{5,18} Thus, current guidelines for children with ALL recommend ASP re-exposure only in patients who within 48 hours have no symptoms, normalized pancreatic enzymes, and no evidence of pseudocysts or necrosis.²³ Of note, these guidelines are based on classification of acute pancreatitis according to the original Atlanta criteria—distinguishing between severe (lasting > 48 hours) and nonsevere (lasting ≤ 48 hours) acute pancreatitis.^{41,42} For adolescents and adults with ALL, some expert panel guidelines recommend permanent discontinuation of ASP for clinically acute pancreatitis (vomiting and severe abdominal pain with elevated pancreatic enzymes above 3 times the upper normal limit and/or pseudocyst development).⁴³ However, the pressing question in relation to (1) the AAP risk in AAP-naïve patients, (2) the risk of a second AAP episode after ASP re-exposure, and (3) overall survival after AAP-related ASP truncation remains unanswered: Who needs more, less, or no ASP? In that respect, the lack of association between characteristics of the first and second AAP is important, which supports that the decision on re-exposure primarily should reflect the anticipated risk of leukemic relapse—except for patients having persisting symptoms from their first AAP.

The main strengths of this study include the international, multicenter, and population-based design and the inclusion of uniformly treated patients with the same diagnosis across a wide age span. Additionally, the online mandatory prospective and systematic registration of 20 predefined treatment-related toxicities strengthens the reliability of the findings.²⁷

The limitations include the lack of power regarding the analyses of leukemic relapse and second AAP event. Moreover, a potential introduction of selection bias in favor of patients with clear-cut symptoms exists because no systematic screening of AAP was performed in patients with abdominal pain or systemic inflammatory response syndrome. Thus, AAP can easily be misinterpreted as sepsis, unless pancreatic enzyme levels are measured.¹⁸ Still, the impact of age on AAP incidence and risk of complications stands strong, and it is unlikely that these potential weaknesses would have markedly influenced the findings.

In conclusion, older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. ASP re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of ASP treatment intensity increases the risk of relapse.^{4,44,45}

AFFILIATIONS

- ¹Rigshospitalet, Copenhagen, Denmark
- ²University of Copenhagen, Copenhagen, Denmark
- ³Aarhus University Hospital, Aarhus, Denmark
- ⁴Herlev University Hospital, Herlev, Denmark
- ⁵Odense University Hospital, Odense, Denmark
- ⁶Uppsala University Hospital, Uppsala, Sweden
- ⁷Karolinska University Hospital, Stockholm, Sweden
- ⁸Queen Silvia Children's Hospital, Gothenburg, Sweden
- ⁹Umeå University, Umeå, Sweden
- ¹⁰Skåne University Hospital, Lund, Sweden
- ¹¹Trondheim University Hospital, Trondheim, Norway
- ¹²Oslo University Hospital, Oslo, Norway
- ¹³University of Oslo, Oslo, Norway
- ¹⁴Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
- ¹⁵Vilnius University, Vilnius, Lithuania
- ¹⁶Helsinki University Hospital, Helsinki, Finland
- ¹⁷Tallinn Children's Hospital, Tallinn, Estonia
- ¹⁸Tartu University Hospital, Tartu, Estonia
- ¹⁹Reykjavik University Hospital, Reykjavik, Iceland

CORRESPONDING AUTHOR

Kjeld Schmiegelow, MD, DrMedSci, Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark; e-mail: Kjeld.Schmiegelow@regionh.dk.

SUPPORT

Supported by research grants from the Research Foundation of Rigshospitalet (University of Copenhagen; CUR), Krista and Viggo Petersen's Foundation (Litra D/6034-29; CUR), the Danish Childhood Cancer Foundation (KS), and the Danish Cancer Society (KS; BOW).

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT

Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI <https://doi.org/10.1200/JCO.19.02208>.

REFERENCES

1. Toft N, Birgens H, Abrahamsson J, et al: Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. *Leukemia* 32: 606-615, 2018
2. Rank CU, Toft N, Tuckuviene R, et al: Thromboembolism in acute lymphoblastic leukemia: Results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. *Blood* 131:2475-2484, 2018
3. Kearney SL, Dahlberg SE, Levy DE, et al: Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. *Pediatr Blood Cancer* 53:162-167, 2009
4. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. *Blood* 97:1211-1218, 2001
5. Wolthers BO, Frandsen TL, Abrahamsson J, et al: Asparaginase-associated pancreatitis: A study on phenotype and genotype in the NOPHO ALL2008 protocol. *Leukemia* 31:325-332, 2017
6. Samarasinghe S, Dhir S, Slack J, et al: Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. *Br J Haematol* 162:710-713, 2013
7. Raja RA, Schmiegelow K, Albertsen BK, et al: Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. *Br J Haematol* 165:126-133, 2014
8. Moghrabi A, Levy DE, Asselin B, et al: Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. *Blood* 109:896-904, 2007
9. Liu C, Yang W, Devidas M, et al: Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. *J Clin Oncol* 34: 2133-2140, 2016
10. Vora A, Goulden N, Mitchell C, et al: Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial. *Lancet Oncol* 15:809-818, 2014
11. Vrooman LM, Stevenson KE, Supko JG, et al: Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. *J Clin Oncol* 31:1202-1210, 2013

AUTHOR CONTRIBUTIONS

Conception and design: Cecilie U. Rank, Benjamin O. Wolthers, Thomas L. Frandsen, Nina Toft, Peder S. Wehner, Arja Harila-Saari, Petter Quist-Paulsen, Ulla Wartiovaara-Kautto, Ólafur G. Jónsson, Kjeld Schmiegelow

Administrative support: Birgitte K. Albertsen

Provision of study materials or patients: Birgitte K. Albertsen, Ulrik M. Overgaard, Arja Harila-Saari, Johan Malmros, Jonas Abrahamsson, Ulrika Norén-Nyström, Beata Tomaszewska-Toporska, Bendik Lund, Laimonas Griškevičius, Ulla Wartiovaara-Kautto, Mari Punab, Kjeld Schmiegelow

Collection and assembly of data: Cecilie U. Rank, Benjamin O. Wolthers, Birgitte K. Albertsen, Thomas L. Frandsen, Ulrik M. Overgaard, Nina Toft, Peder S. Wehner, Arja Harila-Saari, Johan Malmros, Mats M. Heyman, Jonas Abrahamsson, Ulrika Norén-Nyström, Beata Tomaszewska-Toporska, Bendik Lund, Kirsten B. Jarvis, Petter Quist-Paulsen, Goda E. Vaitkeviciene, Laimonas Griškevičius, Mervi Taskinen, Ulla Wartiovaara-Kautto, Kristi Lepik, Mari Punab, Ólafur G. Jónsson, Kjeld Schmiegelow

Data analysis and interpretation: Cecilie U. Rank, Benjamin O. Wolthers, Kathrine Grell, Birgitte K. Albertsen, Thomas L. Frandsen, Nina Toft, Ove J. Nielsen, Mats M. Heyman, Bendik Lund, Petter Quist-Paulsen, Ulla Wartiovaara-Kautto, Kjeld Schmiegelow

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

We sincerely thank the acute lymphoblastic leukemia (ALL) patients, colleagues, and research nurses at the ALL centers for contributing to the study, reporting data to the NOPHO ALL registry, and completing the questionnaires. We also thank Kirsten Kørup Rasmussen, Louise Rold Helt, and Pernille Rudebeck Mogensen (Pediatric Research Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark) for data extraction help.

12. Duval M, Suci S, Ferster A, et al: Comparison of *Escherichia coli*-asparaginase with *Erwinia*-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. *Blood* 99:2734-2739, 2002
13. Sahu S, Saika S, Pai SK, et al: L-asparaginase (Leunase) induced pancreatitis in childhood acute lymphoblastic leukemia. *Pediatr Hematol Oncol* 15:533-538, 1998
14. Place AE, Stevenson KE, Vrooman LM, et al: Intravenous pegylated asparaginase versus intramuscular native *Escherichia coli* L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): A randomised, open-label phase 3 trial. *Lancet Oncol* 16:1677-1690, 2015
15. Barry E, DeAngelo DJ, Neuberg D, et al: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. *J Clin Oncol* 25:813-819, 2007
16. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. *N Engl J Med* 338:1663-1671, 1998
17. Aldoss I, Pullarkat V, Martinez D, et al: The number of PEG-asparaginase doses administered is a determinant of relapse risk in adult ALL treated with a pediatric-like regimen. *Blood* 122:3915, 2013
18. Wolthers BO, Frandsen TL, Baruchel A, et al: Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: An observational Ponte di Legno Toxicity Working Group study. *Lancet Oncol* 18:1238-1248, 2017
19. Müller HJ, Boos J: Use of L-asparaginase in childhood ALL. *Crit Rev Oncol Hematol* 28:97-113, 1998
20. Frossard JL, Steer ML, Pastor CM: Acute pancreatitis. *Lancet* 371:143-152, 2008
21. Forsmark CE, Vege SS, Wilcox CM: Acute pancreatitis. *N Engl J Med* 375:1972-1981, 2016
22. Flores-Calderón J, Exiga-González E, Morán-Villota S, et al: Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase. *J Pediatr Hematol Oncol* 31:790-793, 2009
23. Raja RA, Schmiegelow K, Frandsen TL: Asparaginase-associated pancreatitis in children. *Br J Haematol* 159:18-27, 2012
24. Wolthers BO, Mogensen PR, Frandsen TL, et al: Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer* 66:e27437, 2019
25. Knoderer HM, Robarge J, Flockhart DA: Predicting asparaginase-associated pancreatitis. *Pediatr Blood Cancer* 49:634-639, 2007
26. Wolthers BO, Frandsen TL, Patel CJ, et al: Trypsin-encoding *PRSS1-PRSS2* variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: A Ponte di Legno toxicity working group report. *Haematologica* 104:556-563, 2019
27. Frandsen TL, Heyman M, Abrahamsson J, et al: Complying with the European Clinical Trials directive while surviving the administrative pressure - An alternative approach to toxicity registration in a cancer trial. *Eur J Cancer* 50:251-259, 2014
28. Toft N, Birgens H, Abrahamsson J, et al: Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Eur J Haematol* 96:160-169, 2016
29. Schmiegelow K, Attarbaschi A, Barzilai S, et al: Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus. *Lancet Oncol* 17:e231-e239, 2016
30. Tram Henriksen L, Gottschalk Højfeldt S, Schmiegelow K, et al: Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-pharmacokinetics and antibody formation. *Pediatr Blood Cancer* 64:e26686, 2017
31. Toft N, Birgens H, Abrahamsson J, et al: Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. *Eur J Haematol* 90:404-412, 2013
32. Albertsen BK, Grell K, Abrahamsson J, et al: Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: A NOPHO ALL2008 randomized study. *J Clin Oncol* 37:1638-1646, 2019
33. Nysom K, Mølgaard C, Hutchings B, et al: Body mass index of 0 to 45-y-old Danes: Reference values and comparison with published European reference values. *Int J Obes Relat Metab Disord* 25:177-184, 2001
34. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al: Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. *Leukemia* 29:526-534, 2015
35. Ribera JM, Oriol A, Sanz MA, et al: Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. *J Clin Oncol* 26:1843-1849, 2008
36. Agirbasli M, Agaoglu NB, Orak N, et al: Sex hormones and metabolic syndrome in children and adolescents. *Metabolism* 58:1256-1262, 2009
37. Dimitrijevic-Sreckovic V, Colak E, Djordjevic P, et al: Prothrombotic factors and reduced antioxidative defense in children and adolescents with pre-metabolic and metabolic syndrome. *Clin Chem Lab Med* 45:1140-1144, 2007
38. Verlaan M, Roelofs HM, van-Schaik A, et al: Assessment of oxidative stress in chronic pancreatitis patients. *World J Gastroenterol* 12:5705-5710, 2006
39. Robles L, Vaziri ND, Ichii H: Role of oxidative stress in the pathogenesis of pancreatitis: Effect of antioxidant therapy. *Pancreat Disord Ther* 3:112, 2013
40. Tong WH, Pieters R, Kaspers GJ, et al: A prospective study on drug monitoring of PEGasparaginase and *Erwinia* asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. *Blood* 123:2026-2033, 2014
41. Bradley EL III: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. *Arch Surg* 128:586-590, 1993
42. Banks PA, Bollen TL, Dervenis C, et al: Classification of acute pancreatitis--2012: Revision of the Atlanta classification and definitions by international consensus. *Gut* 62:102-111, 2013
43. Stock W, Douer D, DeAngelo DJ, et al: Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: Recommendations of an expert panel. *Leuk Lymphoma* 52:2237-2253, 2011
44. Pieters R, Hunger SP, Boos J, et al: L-asparaginase treatment in acute lymphoblastic leukemia: A focus on *Erwinia* asparaginase. *Cancer* 117:238-249, 2011
45. Højfeldt SG, Grell K, Abrahamsson J, et al: Relapse following truncation of asparaginase in NOPHO ALL2008, Nordic Society of Paediatric Haematology and Oncology 37th Annual Meeting. Aalborg, Denmark, May 3-7, 2019



AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/journal/jco/site/ifc.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Cecilie U. Rank

Travel, Accommodations, Expenses: Lundbeck

Benjamin O. Wolthers

Employment: Novo Nordisk

Birgitte K. Albertsen

Honoraria: Shire

Research Funding: Erytech Pharma (Inst)

Mats M. Heyman

Honoraria: Pfizer (Inst), Servier (Inst)

Research Funding: Pfizer (Inst), Servier (Inst)

Ulla Wartiovaara-Kautto

Honoraria: Pfizer, Sanofi

Consulting or Advisory Role: Pfizer, Celgene

Travel, Accommodations, Expenses: Roche, Pfizer

No other potential conflicts of interest were reported.